DMKPQ (DMK Pharmaceuticals) Piotroski F-Score: 0 (As of Jun. 27, 2026)


DMKPQ DMK Pharmaceuticals Corp DMKPQ
16 GF Score
Price $0.00
View Full Analysis

What is DMK Pharmaceuticals Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DMK Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for DMK Pharmaceuticals's Piotroski F-Score or its related term are showing as below:

DMK Pharmaceuticals  (OTCPK:DMKPQ) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


DMK Pharmaceuticals Piotroski F-Score Related Terms


DMK Pharmaceuticals Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for DMK Pharmaceuticals's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DMK Pharmaceuticals Piotroski F-Score Chart

DMK Pharmaceuticals Annual Data
Trend Mar13 Mar14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.00 3.00 1.00 3.00 5.00

DMK Pharmaceuticals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 5.00 4.00 4.00 4.00
DMKPQ
16GF Score
DMK Pharmaceuticals Corp DMKPQ
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Sep23) TTM:Last Year (Sep22) TTM:
Net Income was -3.328 + -8.943 + -8.574 + -1.388 = $-22.23 Mil.
Cash Flow from Operations was -1.522 + -1.548 + -2.569 + -3.737 = $-9.38 Mil.
Revenue was 2.151 + 1.453 + 0.007 + 0.009 = $3.62 Mil.
Gross Profit was -0.331 + -0.335 + -0.354 + -0.329 = $-1.35 Mil.
Average Total Assets from the begining of this year (Sep22)
to the end of this year (Sep23) was
(12.137 + 10.931 + 9.076 + 4.749 + 8.957) / 5 = $9.17 Mil.
Total Assets at the begining of this year (Sep22) was $12.14 Mil.
Long-Term Debt & Capital Lease Obligation was $0.00 Mil.
Total Current Assets was $7.87 Mil.
Total Current Liabilities was $13.46 Mil.
Net Income was -8.774 + -10.355 + -8.397 + -4.399 = $-31.93 Mil.

Revenue was -1.159 + 1.155 + 0.04 + 1.506 = $1.54 Mil.
Gross Profit was -2.824 + -0.309 + -0.649 + -0.142 = $-3.92 Mil.
Average Total Assets from the begining of last year (Sep21)
to the end of last year (Sep22) was
(45.076 + 38.298 + 30.549 + 17.694 + 12.137) / 5 = $28.7508 Mil.
Total Assets at the begining of last year (Sep21) was $45.08 Mil.
Long-Term Debt & Capital Lease Obligation was $0.06 Mil.
Total Current Assets was $10.09 Mil.
Total Current Liabilities was $8.87 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DMK Pharmaceuticals's current Net Income (TTM) was -22.23. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

DMK Pharmaceuticals's current Cash Flow from Operations (TTM) was -9.38. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Sep22)
=-22.233/12.137
=-1.83183653

ROA (Last Year)=Net Income/Total Assets (Sep21)
=-31.925/45.076
=-0.70824829

DMK Pharmaceuticals's return on assets of this year was -1.83183653. DMK Pharmaceuticals's return on assets of last year was -0.70824829. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

DMK Pharmaceuticals's current Net Income (TTM) was -22.23. DMK Pharmaceuticals's current Cash Flow from Operations (TTM) was -9.38. ==> -9.38 > -22.23 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Sep23)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep22 to Sep23
=0/9.17
=0

Gearing (Last Year: Sep22)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Sep21 to Sep22
=0.063/28.7508
=0.00219124

DMK Pharmaceuticals's gearing of this year was 0. DMK Pharmaceuticals's gearing of last year was 0.00219124. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Sep23)=Total Current Assets/Total Current Liabilities
=7.872/13.462
=0.58475709

Current Ratio (Last Year: Sep22)=Total Current Assets/Total Current Liabilities
=10.088/8.874
=1.13680415

DMK Pharmaceuticals's current ratio of this year was 0.58475709. DMK Pharmaceuticals's current ratio of last year was 1.13680415. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

DMK Pharmaceuticals's number of shares in issue this year was 7.066. DMK Pharmaceuticals's number of shares in issue last year was 2.143. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=-1.349/3.62
=-0.37265193

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=-3.924/1.542
=-2.54474708

DMK Pharmaceuticals's gross margin of this year was -0.37265193. DMK Pharmaceuticals's gross margin of last year was -2.54474708. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Sep22)
=3.62/12.137
=0.29826151

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Sep21)
=1.542/45.076
=0.03420889

DMK Pharmaceuticals's asset turnover of this year was 0.29826151. DMK Pharmaceuticals's asset turnover of last year was 0.03420889. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+1+0+0+1+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

DMK Pharmaceuticals has an F-score of 4 indicating the company's financial situation is typical for a stable company.


DMK Pharmaceuticals Business Description

Address 11682 El Camino Real, Suite 300, San Diego, CA, USA, 92130
DMK Pharmaceuticals Corp Formerly Adamis Pharmaceuticals Corp is a specialty biopharmaceutical company focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Its products and product candidates in the allergy, respiratory, and opioid overdose markets include SYMJEPI (epinephrine) Injection 0.3mg and Injection 0.15mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; a naloxone injection product candidate, ZIMHI, based on the approved Symject injection device and intended for the treatment of opioid overdose; Tempol, an investigational drug; and a Beclomethasone metered dose inhaler product candidate (APC-400) intended for the treatment of Covid-19.
16GF Score

Get the complete analysis for DMKPQ

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price